Gossamer Bio, Inc. · NASDAQ:GOSS
Gossamer Bio — ECCO'21 Virtual Congress (June 2021)
8 slides from Gossamer Bio's conference presentation, Jun 4, 2021
Slide 1: Target Engagement and Pharmacodynamic Biomarker Analysis Following Treatment with GB004
Target Engagement and Pharmacodynamic Biomarker Analysis Following Treatment with the Oral Gut-Targeted HIF-1α Stabilizer GB004 in a Phase 1b Trial in Active Ulcerative Colitis William J. Sandborn University of California San Diego, La Jolla, CA, USA On behalf of co-authors: Zhaoqing Ding1, Robin Os
Slide 2: Disclosures of potential conflicts of interest
Disclosures of potential conflicts of interest Sandborn, William:|:|WJS reports: research grants from Abbvie, Abivax, Arena Pharmaceuticals, Boehringer Ingelheim, Celgene, Genentech, Gilead Sciences, Glaxo Smith Kline, Janssen, Lilly, Pfizer, Prometheus Biosciences, Seres Therapeutics, Shire, Takeda
Slide 3: GB004 Phase 1b Study in Ulcerative Colitis
GB004 Phase 1b Study in Ulcerative Colitis Background • UC is associated with a breakdown of the epithelial barrier1 • GB004 is an oral small molecule stabilizer of hypoxia inducible factor (HIF-1α) that targets epithelial repair and function2-5 • GB004 showed preliminary evidence for histologic imp
Slide 4: Preliminary Evidence for Histologic Improvement and Clinical Activity in Mild-to-Moderate UC
Preliminary Evidence for Histologic Improvement and Clinical Activity in Mild-to-Moderate UC Following Treatment with GB004 Phase 1b Study Design Entry Criteria: Mayo Score 3-12 with evidence of active inflammation on baseline colonic biopsy (RHI > 4 with neutrophils in the epithelium) Exploratory E
Slide 5: Modulation of Fecal Secretory IgA and Calprotectin Levels
Modulation of Fecal Secretory IgA and Calprotectin Levels Following Treatment with GB004 Increase in secretory IgA, consistent with Decrease in fecal calprotectin, consistent with improved gut epithelium and local reduction in mucosal inflammation immune defense Secretory IgA Fecal Calprotectin Incr
Slide 6: Reduction of MPO and Increase of HIF-1α Immunostaining in Biopsies from Sigmoid Colon
Reduction of MPO and Increase of HIF-1α Immunostaining in Biopsies from Sigmoid Colon Following Treatment with GB004 Reduction of MPO positive cells in sigmoid Increase in HIF-1α positive cells in colon, consistent with reduction in local sigmoid colon, consistent with target mucosal (neutrophilic)
Slide 7: Modulation in ITGA6 and TJP1 Gene Expression in Biopsies from Sigmoid Colon
Modulation in ITGA6 and TJP1 Gene Expression in Biopsies from Sigmoid Colon Following Treatment with GB004 Increase in TJP1 expression, consistent Increase in ITGA6 expression, consistent with restoring the integrity of the with increased barrier restitution gut mucosal barrier and migration Tight J
Slide 8: Conclusion
Conclusion • In this exploratory study GB004, an oral, gut-targeted, HIF-1α stabilizer, demonstrated numeric • Increase in HIF-1α positive cells • Increases in gene expression (TJP1, ITGA6) and fecal secretory IgA • Decreases in MPO positive cells and fecal calprotectin • These biomarker results, al